SCHEMBL3474113

SCHEMBL3474113

Cc1cc2nc(C(C)(C)C)c(=O)n(CCC(=O)O)c2cc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.41
PIN1 Q13526 1/20 0.39
SCD O00767 2/20 0.39
KMO O15229 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2B Q13224 2/20 0.38
CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474093 0.89 AKR1C3 (0.43) EGLN1SCDKMOKDM4ERXRA
SCHEMBL3476237 0.87 PIN1 (0.43) PIN1SCDKMOKDM4EALDH1A1
SCHEMBL3350638 0.87 PIN1 (0.45) PIN1SCDKMOGRIN1GRIN2B
SCHEMBL3473761 0.79 S1PR1 (0.41) PIN1SCDKMORXRARXRB
SCHEMBL3474561 0.78 KMO (0.41) PIN1SCDKMOCYP1A2CYP2D6
SCHEMBL3473451 0.78 KMO (0.43) PIN1SCDKMOGRIN1GRIN2B
SCHEMBL3376506 0.77 SCD (0.51) PIN1SCDKMOKDM4EMEN1
SCHEMBL3472626 0.77 PTGDR2 (0.43) SCDKMOKDM4E
SCHEMBL3476567 0.76 GRIN1 (0.41) PIN1SCDKDM4EALDH1A1CYP2D6
SCHEMBL3433129 0.76 SCD (0.47) SCDGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US claimed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US claimed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US disclosed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US disclosed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 EGLN1 721/4885PIN1 4039/4885SCD 2432/4885
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 EGLN1 721/4885PIN1 4039/4885SCD 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.